Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EPS (Weighted Average and Diluted): 2020-2025

Historic EPS (Weighted Average and Diluted) for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -$0.82.

  • Rhythm Pharmaceuticals' EPS (Weighted Average and Diluted) fell 12.33% to -$0.82 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.10, marking a year-over-year increase of 28.41%. This contributed to the annual value of -$4.34 for FY2024, which is 35.62% down from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' EPS (Weighted Average and Diluted) is -$0.82, which was down 9.33% from -$0.75 recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $0.90 in Q1 2021 and a low of -$2.35 during Q1 2024.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.76 (2023), whereas its average is -$0.90.
  • In the last 5 years, Rhythm Pharmaceuticals' EPS (Weighted Average and Diluted) skyrocketed by 215.38% in 2021 and then plummeted by 216.67% in 2022.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.86 in 2021, then grew by 13.95% to -$0.74 in 2022, then climbed by 5.41% to -$0.70 in 2023, then decreased by 2.86% to -$0.72 in 2024, then declined by 12.33% to -$0.82 in 2025.
  • Its last three reported values are -$0.82 in Q3 2025, -$0.75 for Q2 2025, and -$0.81 during Q1 2025.